Harmony Biosciences Holdings, Inc. (HRMY)
| Market Cap | 1.91B -2.2% |
| Revenue (ttm) | 989.36M +19.8% |
| Net Income | 178.60M -3.8% |
| EPS | 3.02 -4.5% |
| Shares Out | 58.72M |
| PE Ratio | 10.78 |
| Forward PE | 8.61 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 582,620 |
| Open | 32.68 |
| Previous Close | 32.98 |
| Day's Range | 32.51 - 33.43 |
| 52-Week Range | 25.90 - 43.49 |
| Beta | 0.98 |
| Analysts | Buy |
| Price Target | 48.08 (+47.53%) |
| Earnings Date | Nov 4, 2026 |
About HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in P... [Read more]
Financial Performance
In 2025, HRMY's revenue was $868.45 million, an increase of 21.51% compared to the previous year's $714.73 million. Earnings were $158.69 million, an increase of 9.07%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for HRMY stock is "Buy." The 12-month stock price target is $48.08, which is an increase of 47.53% from the latest price.
News
Harmony Biosciences to Participate in Upcoming Investor Conferences
PLYMOUTH MEETING, Pa., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that Harmony's management team will participate in the following upcoming inv...
Harmony Biosciences Holdings Earnings Call Transcript: Q3 2026
WAKIX Q3 revenue reached $269M, with 400 net patient adds and FY guidance of $1B-$1.04B reaffirmed. BP-205 MAD results supported continued development, while litigation and a competitor launch remain key watch points.
Harmony Biosciences Holdings Slides: Q3 2026
Harmony Biosciences Holdings has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
Harmony Biosciences Holdings Earnings release: Q3 2026
Harmony Biosciences Holdings released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Harmony Biosciences Holdings Quarterly report: Q3 2026
Harmony Biosciences Holdings has published its Q3 2026 quarterly earnings report on November 4, 2026.
Harmony Biosciences backs FY26 revenue view $1B-$1.04B, consensus $1.03B
08:22 EST Harmony Biosciences (HRMY) backs FY26 revenue view $1B-$1.04B, consensus $1.03B
Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile
WAKIX ® Net Revenue in Q3 of $269 Million; Driven by Strong Demand with 400 Net Patient Adds in the Quarter; Reiterates Full Year Guidance of $1.0B to $1.04B
Harmony Biosciences price target lowered to $49 from $51 at Mizuho
Mizuho lowered the firm’s price target on Harmony Biosciences (HRMY) to $49 from $51 and keeps an Outperform rating on the shares.
Revisiting Former Stock Picks Marriott, Logitech, Harmony Biosciences
Technical indicators have turned bullish for the Barron's Investor Circle stock picks.
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
PLYMOUTH MEETING, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report third quarter 2026 financial results on Wednesday, Novemb...
Harmony Biosciences initiated with a Buy at Ladenburg
Ladenburg initiated coverage of Harmony Biosciences (HRMY) with a Buy rating and $55 price target The firm says the company is leveraging a “platform drug.”
Mizuho positive on Harmony Biosciences CEO transition
After Harmony Biosciences (HRMY) announced that Peter Anastasiou, the company’s current COO, will become President, CEO and a board member, Mizuho analyst Graig Suvannavejh said the news “comes as no…
Harmony Biosciences CEO Jeffrey Dayno to retire, Peter Anastasiou to succeed
Harmony Biosciences (HRMY) announced that, as part of the board of directors’ succession planning, Peter Anastasiou, former Harmony board member and current EVP and COO, has been appointed president, ...
Harmony Biosciences price target raised to $42 from $39 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Harmony Biosciences (HRMY) to $42 from $39 and keeps a Hold rating on the shares after hosting a virtual non-deal roadshow management.
Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 ...
Harmony Biosciences Holdings Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Management outlined a strategy focused on expanding the pipeline with BP-205 and other orexin-2 agonists, targeting both sleep and broader CNS indications. Business development remains a top priority, with multiple deals expected to bridge revenue post-2028, while robust IP defense aims to maintain WAKIX exclusivity through 2030.
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company's investigation of EPX-100...
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 20...
Harmony Biosciences initiated with an Outperform at Wolfe Research
Wolfe Research analyst Rudy Li initiated coverage of Harmony Biosciences (HRMY) with an Outperform rating and $60 price target The firm believes the company’s Wakix base business of can justify…
Harmony Biosciences Holdings Transcript: Piper Sandler Virtual CNS Symposium
Record WAKIX sales are fueling pipeline growth, including BP-205, a potent orexin agonist advancing toward multiple CNS indications. Clemizole shows promise in epilepsy with strong efficacy and safety, while new pitolisant formulations aim to expand market reach and address unmet needs.
Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium
PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Pi...
Harmony Biosciences price target raised to $34 from $29 at Truist
Truist analyst Danielle Brill raised the firm’s price target on Harmony Biosciences (HRMY) to $34 from $29 and keeps a Hold rating on the shares.
Harmony Biosciences price target raised to $39 from $36 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Harmony Biosciences (HRMY) to $39 from $36 and keeps a Hold rating on the shares.
Harmony Biosciences price target raised to $37 from $33 at UBS
UBS raised the firm’s price target on Harmony Biosciences (HRMY) to $37 from $33 and keeps a Neutral rating on the shares. Shares gained on encouraging initial BP-205 human data,…
Harmony Biosciences price target raised to $30 from $28 at BofA
BofA analyst Jason Gerberry raised the firm’s price target on Harmony Biosciences (HRMY) to $30 from $28 and keeps an Underperform rating on the shares. The firm’s raised target reflects…